% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • swhitemd50 swhitemd50 Apr 1, 2012 11:27 PM Flag

    Gilead will lose its lead

    I am betting Gilead will have less than a 60% SVR for GS-7977/ribavirin in genotype 1 naive hepatitis C patients. Why? First, complete failure of GS-7977/ribavirin in genotype 1 null hepatitis C patients. Second, remember that the great results reported for GS-7977 last year were all in easy to treat genotype 2 and 3 hepatitis C. Third, Pharmassett and its 7977 were so massively overhyped that the whole thing is starting to look like a huge deception designed to enrich a lot folks on Wall Street who have already cashed out.

83.23+3.52(+4.42%)Feb 12 4:00 PMEST